The company has also announced several recent appointments to the Zosano leadership team, including Don Brown, COO and president; John Vuko, executive vice president and CFO; Beth Piper, vice president of clinical development; and Stephen Worsley, vice president of business development.
In her new role of chairperson and CEO, Ms Schulze will spearhead Zosano’s strategic and operational initiatives to advance the company’s novel therapeutic programs, including its lead product Zosano PTH patch, a proprietary transdermal patch formulation of parathyroid hormone for the treatment of established osteoporosis.
In addition to her role at Zosano, Ms Schulze has held numerous board positions and is currently a director of Cerus. She was previously CEO of YM Biosciences US and president, YM Biosciences, Inc.
Peter Daddona, chief scientific officer; Greg Yedinak, vice president of manufacturing, and Kim Gaumer, vice president of regulatory affairs and quality assurance, are the new members of Zosano’s senior management team.